Experience MedTrace’s software, aQuant, at ASNC2025 in Orlando

We look forward to showcasing our patented analysis software, aQuant, at the American Society of Nuclear Cardiology’s Annual Scientific Session and Exhibition (ASNC2025), taking place: September 4-7 in Orlando, Florida.

Visit MedTrace at booth no. 115:

  • Experience a live demonstration of MedTrace’s aQuant analysis software. While the product is not yet cleared or approved by the FDA for sale in the U.S., upon full regulatory approval aQuant is expected to provide quantitative myocardial blood flow analysis during PET exams with 15O-water. The version showcased at ASNC 2025, is currently being used in MedTrace’s Phase III Clinical Trial.
  • Discuss the RAPID-WATER-FLOW trial sponsored by MedTrace with the companies dedicated team and get the latest updates on our 15O-water research findings from across our 8 trials. MedTrace’s Phase III Clinical Trial aim to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion PET imaging agent.

Read more about the trial here. 

Stop by or book a meeting in advance: 

We welcome all ASNC2025 attendees interested in MedTrace’s patented software and ongoing Phase III Clinical Trial to connect with us.

Schedule a meeting in advance or stop by booth #115 during the event.

Contact:

René Duvander 
Director, Market Development 
[email protected]  

MedTrace’s technologies presented at ASNC2025 are not cleared to market and available for investigational research only.

About MedTrace

MedTrace is a pharma and medical device company with a 15O-water point-of-care solution under development. The solution consists of patented hardware for on-demand manufacturing, dosing, and infusion of 15O-water and patented software to analyze PET images. The company has an ongoing Phase III Clinical Trial, RAPID-WATER-FLOW, that seeks to evaluate the diagnostic accuracy and safety of  15O-water as a myocardial perfusion PET imaging agent.